CEO Choon-Peng Ng and Vice President of Innovation, Michael Fehlings, Ph.D., will discuss Asia’s role in the “golden age” of biotech and AI in therapeutics

SAN DIEGO & SINGAPORE--(BUSINESS WIRE)--ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that members of its executive team will present at two upcoming conferences, BioCentury-BayHelix East-West Summit 2024 and The State of Precision Medicine 2024.

Here is the upcoming event schedule:

• BioCentury-BayHelix East-West Summit: Singapore – March 4-6, 2024, Marina Bay Singapore
  • Company Presentation
    • Presenter: Choon-Peng Ng, CEO, ImmunoScape
    • Date/Time: March 5, 2024 at 10:15am local time
  • Panel: R&D SHOWCASE #1: HOW WILL ASIA DRIVE BIOTECH’S GOLDEN AGE?
    • Biotech has entered a golden age, with new frontiers in ADCs, bispecifics and cell therapies, new classes of small molecules, and an ever-expanding toolkit for delivering, disrupting and editing genes. What role are Asian innovators playing? Are they creating Hot Spots of innovation in specific technologies or disease areas? And where will Singapore leverage its greatest domain expertise? This panel will dive into the emerging strengths of Asia's biotech Hot Spots and the centers of excellence where Western R&D leaders and investors are looking to the region for innovation.
    • Panelist: Choon-Peng Ng, CEO, ImmunoScape
    • Date/Time: March 5, 2024 at 2:00pm local time
  • More about the event here
• Inside Precision Medicine’s 2^nd Annual “The State of Precision Medicine” Summit – March 6, 2024, Virtual
  • Panelist: Michael Fehlings, Co-Founder, VP of Innovation, ImmunoScape
  • Date/Time: March 6, 2024 at 2:55pm ET
  • Panel: AI for Therapeutics: Upstream Applications; Downstream Challenges
  • Register for free for the virtual event here

To learn more about ImmunoScape and other upcoming events, visit the website.

About ImmunoScape

ImmunoScape is a biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit https://immunoscape.com/.

Contacts

Media:
Kalyn Schieffer for ImmunoScape

[email protected]